No money for energy? Warm yourselves with some billion-dollar biotech research!
ARPA-H is modeled after similar agencies that advance innovation in their sectors, such as the Defense Advanced Research Projects Agency, which is known for contributing to achievements such as the internet, GPS and even Moderna’s vaccine for COVID-19.
If you’re not familiar with DARPA yet, please see these posts first.
What all these ARPAs do is one thing: spend countless billions from public money to do research that’s later handed to private companies through the Public-Private Partnership (PPP) scam. Universities used to provide these services, they still do to a smaller scale, but they can’t be as secretive and can’t be involved in some highly sensitive projects from a national security perspective.
ARPA-H launches path to speed public-private partnerships
The mission of the Advanced Research Projects Agency for Health (ARPA-H) is to advance better health outcomes for everyone. To realize this mission, innovations sparked by ARPA-H must be able to transition into the real world. Transition strategies are often left to the last phase of a program, which significantly reduces the likelihood of a solution to reach the people that need it. ARPA-H seeks to facilitate public-private partnerships for accelerating technology transfer and transition by launching an effort to form Partnership Intermediary Agreements (PIA) that will make transition resources available throughout the entire program life cycle.
“Since the launch of ARPA-H almost a year ago, we have been building the team, tools, and capabilities that each program manager will need in order to launch audacious programs capable of advancing the state of the art in health innovation,” said Renee Wegrzyn, inaugural director of ARPA-H. “The PIA capability is critical to ensure that incoming program managers can hit the ground running and pursue big challenges in health.”
A PIA is an agreement established with a nonprofit partner with deep commercial sector and transition expertise, to engage academia and industry on behalf of the government. Speed and flexibility are the two main advantages of PIAs. PIAs allow for novel approaches that mirror commercial practice to get solutions to market. PIAs are authorized under 15 U.S.C. §3715 to create public-private partnerships.
“We at ARPA-H care deeply about getting solutions to everyone, and this is a powerful tool to ensure those solutions survive in the wild,” said Craig Gravitz, director of ARPA-H’s Project Accelerator Transition Innovation Office (PATIO). “This ensures ARPA-H programs address the market dynamics that matter for success, early and often.” PATIO is ARPA-H’s transition and commercialization office and focuses on ensuring that technologies developed through ARPA-H programs are readily accessible and scalable.
ARPA-H’s PIA application is designed to be easy to understand and implement, enabling potential intermediaries from all eligible communities who may not have deep government expertise to rapidly submit.
The PIA application is now closed. Awards will likely be made approximately 30 days from release date.
Dr. Renee Wegrzyn serves as the first director of the Advanced Research Projects Agency for Health (ARPA-H), appointed on Oct. 11, 2022, by President Joseph R. Biden.
Previously, Wegrzyn served as a vice president of business development at Ginkgo Bioworks and head of innovation at Concentric by Ginkgo, where she focused on applying synthetic biology to outpace infectious diseases – including COVID-19 – through biomanufacturing, vaccine innovation, and biosurveillance of pathogens at scale.
Wegrzyn comes to ARPA-H with experience working for two of the institutions that inspired the creation of the agency – the Defense Advanced Research Projects Agency (DARPA) and Intelligence Advanced Research Projects Activity (IARPA).
As a Program Manager in the DARPA Biological Technologies Office, Wegrzyn leveraged the tools of synthetic biology and gene editing to enhance biosecurity, support the domestic bioeconomy, and thwart biothreats. Her DARPA portfolio included the Living Foundries: 1000 Molecules, Safe Genes; Preemptive Expression of Protective Alleles and Response Elements (PREPARE); and the Detect it with Gene Editing Technologies (DIGET) programs.
Wegrzyn received the Superior Public Service Medal for her work and contributions at DARPA. Prior to joining DARPA, she led technical teams in private industry in the areas of biosecurity, gene therapies, emerging infectious disease, neuromodulation, synthetic biology, as well as research and development teams commercializing multiplex immunoassays and peptide-based disease diagnostics.
Wegrzyn served on the scientific advisory boards for the National Academies Standing Committee on Biotechnology Capabilities and National Security Needs, National Academies of Science Board on Army Research and Development, Revive & Restore, Air Force Research Labs, Nuclear Threat Initiative, and the Innovative Genomics Institute. She holds doctoral and bachelor’s degrees in applied biology from the Georgia Institute of Technology, was a fellow in the Center for Health Security Emerging Leaders in Biosecurity Initiative and completed her postdoctoral training as an Alexander von Humboldt Fellow in Heidelberg, Germany.
With ARPA-H’s billions in Congressional funding and broad mandate to solve intractable health challenges, several audience members asked Wegrzyn what success might look like for the nascent agency. In addition to accelerating breakthroughs in disease prevention and health care delivery, “We want to create tools and products that people want to use,” Wegrzyn said. “We want it to be so obvious to the rest of the world why ARPA-H is here. … So that’ll look like success.” “And paradoxically,” she added, “success should also look like failure.” If the agency doesn’t experience failure, she argues, it may not be taking big enough risks. Another key indicator of success for ARPA-H will be in its diversity — in the problems it solves, in the communities it serves and in the program managers it hires. Spreading the word to people around the world, including those in underrepresented communities, will be pivotal.
The acceleration of COVID-19 testing platforms and vaccine development has demonstrated the possibility of expediting research for similar biomedical breakthroughs. However, the National Institutes of Health (NIH) lacks a framework to regularly sustain this type of research. A new federal agency, the Advanced Research Projects Agency for Health (ARPA-H), offers a unique opportunity to capitalize on the lessons learned from the COVID-19 pandemic and drive federal investment into high-risk, high-reward biomedical research. ARPA-H will mirror the flat bureaucratic structure of the successful Defense Advanced Research Projects Agency (DARPA) through the employment of independent project managers. ARPA-H is also unique in how it centers equity in the agency’s core mission. These unique traits could enable the agency to fill the gaps in current biomedical research under the NIH. Nonetheless, ARPA-H’s implementation is not without challenges: its incorporation within the NIH has raised concerns regarding its ability to specialize in high-risk research and the diversion of funding away from the rest of the NIH. These worries can be mitigated through the separation of ARPA-H and the NIH. Successful implementation of the ARPA-H framework would supplement current NIH work, diversify the US federal research strategy, accelerate promising breakthroughs, promote equity in health, and transform the nature of biomedical research in the US.
And this is not the last ARPA you’ll hear about. We’re in a world of ARPAs.
To be continued? Our work and existence, as media and people, is funded solely by our most generous supporters. But we’re not really covering our costs so far, and we’re in dire needs to upgrade our equipment, especially for video production. Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!
! Articles can always be subject of later editing as a way of perfecting them
Everything you didn’t like about Pentagon’s DARPA, CIA’s In-Q-Tel, and more, but with funds stolen from Queen’s subjects and European peasantry. The business of high-tech slavery is the future and the future is now! Advanced by slave work of course.
UK to host world-leading Nato Defence Innovation Headquarters
The UK will partner with Estonia on the Defence Innovation Accelerator for the North Atlantic (DIANA) programme to maintain NATO’s technological edge.
The United Kingdom, in partnership with Estonia, will host the European HQ of a programme for NATO allies to accelerate, test, evaluate and validate new technologies that address critical defence challenges and contribute to Alliance deterrence.
Announced today by the NATO Secretary General, Jens Stoltenberg, the Defence Innovation Accelerator for the North Atlantic (DIANA) will see transatlantic cooperation on critical technologies and help NATO work more closely with industry and academia.
The UK’s accelerator will be twinned with a new accelerator in Tallinn, Estonia to encourage the sharing of expertise, explore the use of virtual sites to trial vehicles, including autonomous ones, and test cyber innovations.
As hosts, the UK and Estonia will:
Support start-up companies with funding, guidance and business expertise through twinned accelerator networks.
Offer the use of ‘deep tech’ test centres to assess technological solutions to military problems, utilising the Defence BattleLab.
Work with NATO to develop a virtual marketplace to connect start-ups with trusted investors, as well as a rapid acquisition service to connect products to buyers at pace.
UK Defence Secretary, Ben Wallace said:
The UK and Estonia are two of the most innovative countries in NATO and our hosting of DIANA will harness that innovation for the benefit of all Allies tackling future military threats.
The UK has a vibrant tech community, combining the academia, financiers, and high-tech start-ups that make it an ideal place to develop the next generation of military technologies.
Estonia was the natural partner for the UK given its international leadership in cyber, autonomy and AI, and our close partnership forged through the Enhanced Forward Presence.
Ranked in the world’s top ten innovative universities, Imperial College London will bring together academia, industry and government by hosting the headquarters of DIANA and a DIANA Accelerator at the Innovation Hub (IHUB) in the White City Innovation District, in a space shared with the UK’s Defence and Security Accelerator (DASA), Major Defence Contractors and The US Department of Defence’s Tri-Service Office.
Supported by DASA, the UK and Estonia DIANA HQ is expected to be operational from July 2022. DIANA is essential to delivering the NATO 2030 vision and ensuring that the Alliance develops the military capabilities needed to deter and defend against existing and future threats.
Estonian Defence Minister, Kalle Laanet.
The goal of DIANA is to support deep technologies companies that contribute to defence. It will bring together talented innovators with new technologies end-users in the area of defence. We are very glad to see that the good cooperation we have with the UK will expand even further and also encompass our universities and private sector more,
Cooperation between the UK and Estonia is working well on every level because we have a common understanding of defence policy. Good relations with Allies is a cornerstone of Estonian defence policy, and a successful start to this programme for us is a sign that this cornerstone is strong.
Co- Director, Institute for Security Science and Technology, Imperial College London, Professor Deeph Chana, said:
As one of the top STEM-B universities in the world, in one of the most diverse cities, Imperial College London is uniquely placed to power a progressive, responsible and holistic dual-use security and defence technology innovation program by hosting DIANA. Coordinated through our Institute for Security Science and Technology and Business School we’re committed to working on disruptive research and innovation to reduce insecurity and to deal with global threats and challenges.
DIANA will support all seven of the key emerging and disruptive technologies that NATO has identified as priorities: artificial intelligence, big-data processing, quantum-enabled technologies, autonomy, biotechnology, hypersonics and space.
🇪🇪 and 🇬🇧 are set to create the European HQ of #DIANA, @NATO's defence innovation accelerator. #Estonia will also host a NATO startup accelerator.
This will: ➡️support deep tech defence companies; ➡️link up innovation sites; ➡️strengthen the transatlantic innovation community. https://t.co/bCXKPfHssQ
Estonia chosen as one of the initiators of the NATO DIANA future technologies programme
5. April 2022 – 19:13
At the NATO summit last June in Brussels, NATO leaders decided to create an innovation accelerator – the DIANA (Defence Innovation Accelerator for the North Atlantic) programme will allow Allies to join their strengths in developing and adopting new and breakthrough technologies in the area of security and defence.
In cooperation between the Estonian ministries of defence, foreign affairs, and economic affairs and communication, Estonia and the United Kingdom submitted a bid for the programme, which was approved in full at the proposal of the NATO Secretary General. Together with the UK, Estonia is set to create the DIANA European headquarters, a NATO start-up accelerator will be founded in Estonia, and several existing testing sites for new technologies will be added to the DIANA accelerator network.
“The goal of DIANA is to support deep technologies companies that contribute to defence. It will bring together talented innovators with new technologies end-users in the area of defence. We are very glad to see that the good cooperation we have with the UK will expand even further and also encompass our universities and private sector more,” commented Minister of Defence Kalle Laanet. “Cooperation between the UK and Estonia is working well on every level because we have a common understanding of defence policy. Good relations with Allies is a cornerstone of Estonian defence policy, and a successful start to this programme for us is a sign that this cornerstone is strong.”
“Estonia and the UK are two of the most innovative nations in the Alliance, hosting respectively the most unicorn firms per capita, and the most unicorns in total. With Estonia’s impressive leadership in cyber, autonomy and AI, and the close partnership forged through our enhanced Forward Presence (eFP), they were a natural partner for the UK on this important initiative,” said UK Defence Secretary Ben Wallace.
“Trust in this Estonian initiative is a sign of our good reputation in creating favourable ecosystems for start-up innovation and developing new technologies. The fact that DIANA will be launched both in Estonia and the UK is an example of cooperation at work – both domestically between ministries, universities and the private sector, as well as across borders,” added Minister of Foreign Affairs Eva-Maria Liimets.
DIANA is a highly ambitious cooperation format that will bring together civil and military experts to develop and implement dual-use technologies in member states as well as across the transatlantic Alliance.
In addition, Estonia will participate at the negotiations for the founding of a NATO innovation fund. The objective of the fund is to support dual-use deep technology start-ups with investments, by offering trusted capital and creating additional opportunities for growth. States that have decided to join the fund will formalise the agreement at the NATO summit set to take place at the end of June.
Going forward, Estonia will continue preparations for the launch of the DIANA programme in 2023.
NATO, the intergovernmental defence alliance between 30 European and North American countries, launches a €1B fund and an accelerator targeting deeptech startups in the defence sector. The goal is to leverage the innovation capabilities of startups to develop the next generation of war machines. Part of NATO 2030, the move follows a period of concern for Alliance leaders regarding China’s increased reliance on tech for its military strategy.
At the end of two virtual meetings in early June, Foreign and Defence ministers agreed on the need to reinforce the transatlantic defence partnership between Europe and North America amid intensifying global competition. “We need to sharpen our technological edge (…) We see that new and disruptive technologies, such as autonomous systems, artificial intelligence, and big data are really changing the way our militaries are going to operate in the future,” NATO Secretary-General Jens Stoltenberg said.
Planning to stay ahead of the curve is particularly important, as China has been investing heavily in new technologies to strengthen its military power and fuel its ambition to become a leader in the use of AI. The defence accelerator is also a recognition from European and North American leaders of the prevalence of disruptive technologies – and a decision to harness their unique potential to strengthen common defence strategies.
How startups benefit from NATO’s initiative
For startups, this will be an opportunity to work together with the government sector and academia towards accelerating the achievement of national security and transatlantic collaboration goals. “Sometimes a technology company may not realize that their product could be viable for the defence community,” David van Weel said. Startups will also benefit from entering a network of stakeholders that can help them develop and get funded.
DIANA will be supporting startups working on either of the seven key emerging and disruptive technologies (EDTs) that NATO deems critical for the future: AI, big-data processing, quantum-enabled tech, autonomy, biotechnology, hypersonics, and space.
The accelerator includes a trusted capital marketplace that will enable funding opportunities for companies by connecting them to pre-qualified investors. Additionally, startups will receive support through a venture capital fund. The NATO Innovation Fund has been set up to support companies developing dual-use and key tech that could serve the Alliance. The fund will be an opt-in for member countries and would be underwritten by about €70M per year. Van Weel added that NATO would be looking for a partner from the private sector to help run the daily business operations of the fund.
DIANA is unique to NATO’s innovation efforts in that it has been built with the needs of the startup community in mind. It specifically targets early-stage startups rather than larger companies and traditional defence firms, in order to harness their unique ability for innovation.
IF YOU’RE NAIVE ENOUGH TO THINK THIS IS ABOUT DEFENSE, AND NOT THE INSANE DAVOS TRANSHUMANIST AGENDA…
… I will bring to your attention the fact that NATO has already adopted its own “Agenda 2030”, titled “NATO 2030”, and both of these are just “The Great Reset for Different Niches of Dummies” in their specific lingo. That’s all they are. Proportionally, “NATO 2030” talks about climate change about as much as “The Great Reset”.
Also note how NATO presents itself more and more as a business accelerator. Transhumanist businesses with a multinational army funded by half a billion unsuspecting dupes and NPCs in NATO countries and beyond. What could go wrong, right?
NATO hopes to launch new defense tech accelerator by 2023
Secretary-General Jens Stoltenberg gives press conference at the NATO summit in Brussels on June 14, 2021. (Photo by FREDERIC SIERAKOWSKI/BELGA MAG/AFP via Getty Images)
STUTTGART, Germany — In less than two years, NATO hopes to have its own, modified version of the U.S. Defense Advanced Research Projects Agency (DARPA) up and running.
Alliance members agreed at the 31st annual summit, held June 14 in Brussels, to launch a new initiative dubbed the Defence Innovation Accelerator of the North Atlantic, or DIANA, meant to speed up trans-Atlantic cooperation on critical technologies, and help NATO work more closely with private-sector entities, academia and other non-governmental entities.
The goal is to have DIANA reach initial operating capability (IOC) by 2023, David van Weel, assistant secretary-general for emerging security challenges, said at a Tuesday virtual roundtable with reporters. By next year, the hope is to have “the initial parts … starting to come up into fruition,” he added.
In the long term, DIANA will have headquarters both in North America and in Europe, and link to existing test centers throughout NATO member countries that will be used for “validating, testing, and co-designing applications in the field of emerging and disruptive technologies,” van Weel said. DIANA will also be responsible for building and managing a network meant to help relevant startups grow and support NATO’s technology needs via grant programs.
The focus will be on national security and defense purposes, and DIANA will not ask for or solicit companies’ intellectual property, van Weel noted.
While he singled out artificial intelligence, big-data processing, and quantum-enabled technologies, DIANA is meant to support all seven of the key emerging and disruptive technologies — or EDTs — that NATO has identified as critical for the future. The other four include: autonomy, biotechnology, hypersonics and space.
Sometimes a technology company may not realize that their product could be viable for the defense community, he added.
One key component of DIANA will be a trusted capital marketplace, where smaller companies can connect with pre-qualified investors who are interested in supporting NATO’s technology efforts. Ensuring that investors are vetted ahead of time will allow NATO to ensure “that the technology will be protected from illicit transfers,” van Weel said.
Members also agreed for the first time to build up a venture capital fund to support companies developing dual-use and key technologies that could be useful to NATO, and which will be optional for member-nations to participate in. The NATO Innovation Fund, as it’s called, would have a running time of about 15 years to start, and would be underwritten by about 70 million euro (about $83 million) per year, per van Weel.
The goal is not for NATO headquarters or for its member-nations to run the innovation fund, he noted. “The actual running of a venture capital fund, we believe, should be done by companies that have a broad range of experience in the field.” He cited the U.S.-based capital venture firm In-Q-Tel as an example of the type of partner NATO would seek to run the “day-to-day” business of the fund.
“I read somewhere that NATO is not a bank—we’re not,” van Weel said. “But it will be the nations providing the funds, and giving the general direction.”
These two initiatives of a technology accelerator and innovation fund are “hopefully going to … bring the alliance forward into the 21st century,” van Weel said.
NATO has previously invested in information technology (IT) and software through the NATO Communications and Information Agency (NCIA), but the difference with the innovation fund, and DIANA, is that the alliance wants to better connect with early-stage startups, rather than larger software companies or traditional defense firms, van Weel said.
“DIANA is not about taking over innovation for the NATO enterprise,” he said. “It’s a different community, and requires different funding mechanisms and different types of engagement.”
But it is still early days. While the IOC goal is 2023, “step one is we want to know from allies what they want to offer to DIANA,” van Weel said. Once the NATO Innovation Fund has its participating members, for example, a charter will be set up that will lay out the funding models, rapid contracting processes, and leadership guidelines.
“We are trying to do this as fast as we can,” van Weel assured, but then noted, “we do want to get it right, because … with the startup community, you only get one chance.”
If you want to deepen your understanding of the situation and the context here, also read:
To be continued? Our work and existence, as media and people, is funded solely by our most generous supporters. But we’re not really covering our costs so far, and we’re in dire needs to upgrade our equipment, especially for video production. Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!
! Articles can always be subject of later editing as a way of perfecting them
Imagine that the brutal experiments at Auschwitz were better concealed and the prisoners were drugged and brainwashed to believe that’s the best world out there for them. Then find out that the management has never stopped winning, expanding and perfecting their business model, up to today’s Great Reset.
Founded in Binghamton, New York, in 1901, Ansco was a manufacturer of photographic products and film. Ansco was originally founded through the merger of E. Anthony & Company and Scovill Manufacturing. In 1928, Ansco merged with Agfa to form Agfa-Ansco. The new corporation was a division of General Aniline and Film (GAF) Corporation, which was controlled by the German chemical cartel IG Farben. After Germany declared war on the United States in 1941, the United States Government seized the assets of GAF, including Agfa-Ansco. In 1943, the company removed “Agfa” from its name, once again becoming Ansco. The United States Justice Department oversaw Ansco’s operation until 1965, when government-held stock in GAF was sold to the public. In 1977, GAF eliminated its line of consumer photography products, including those manufactured by Ansco at the Binghamton facility. GAF also sold the Ansco trademark to Haking Enterprises. GAF continued to manufacture film at the Binghamton plant for industrial and medical use until 1981, when it sold the plant to Anitec Image Corporation. Over the next two decades, the former Ansco facility was sold several times, and in 2000, it was demolished.
Prior to the late 1970s, dozens of asbestos-containing materials were utilized in the construction and maintenance of buildings at Ansco’s Binghamton facility, including fireproof insulation, pipe covering and insulating cement. Inhaling dust from the application and removal of asbestos-containing materials placed workers at risk for developing an asbestos-related disease, such as mesothelioma or lung cancer.
Fireproof insulation was applied to structural steel during the construction of buildings at Ansco. Fireproofing materials were manufactured as a dry mixture of asbestos, linen and cement, packaged in fifty-pound paper bags. The dry mixture was mixed with water and sprayed onto the structural steel using a hose. Pouring, mixing and spraying fireproof insulation created clouds of asbestos-containing dust. After the fireproofing material was applied, it was typical for tradesmen, such as electricians or pipefitters, to scrape the fireproofing material from structural steel in order to install pipes and conduits. When the fireproof insulation was disturbed, asbestos fibers and dust became airborne.
Workers applied asbestos-containing pipe covering to pipes at the Binghamton Ansco facility. Pipe covering was applied to numerous piping systems in order to maintain stable internal temperatures and to protect pipes from damage. When pipe covering was applied, asbestos fibers were emitted. Insulating cement was also applied to pumps, valves and other equipment. It was manufactured as a powder and mixed with water to prepare it for application. Mixing insulating cement caused asbestos-containing dust to become airborne.
What’s Bayer been up to lately? We find out from their website:
The Bio Revolution is redefining innovation in the life sciences. How this might be a game changer.
The life sciences have made great advances in the past years. Biology, life sciences and the megatrend of digitization are growing closer together, enabling new inventions that impact our daily lives in a scope that we speak of a Bio Revolution. This revolution is reinforced by rapid increases in computing power and the emergence of new capabilities in AI, automation, and data analytics. These trends are further accelerating the pace of innovation and the potential for higher R&D productivity in the life sciences.
All this has led to new ways to understand and explore biology. The range of life forms on earth is incredibly complex and diverse. However, the methods to analyze them can be remarkably similar. Technologies and methods are transcending disciplinary boundaries even faster.
The implications across the life sciences can be enormous:
For human health, for example, a deeper understanding of the relationship between genetics and disease has led to the emergence of precision medicine, which can potentially be more effective than the one-size-fits-all therapies of the past. In the future, new technologies could help the healthcare industry not only treat, but cure or even prevent diseases. New gene and cell therapies, for example, aim to cure genetic diseases, potentially enabling sustainable organ replacement or reversing autoimmune diseases.
The Bio Revolution has the potential to help address some of the most critical global challenges, from climate change to pandemics, chronic diseases, and worldwide food security. Experts estimate that a significant portion of the economic impact of biological applications will be in health care, agriculture, and consumer products.3 Already today, the Bio Revolution with its convergence of science and technology has created an explosion of research projects in science and business. Each year, the amount of Intellectual Property related to the Bio Revolution is increasing.4 This can be seen, for example, by the number of patents in CrispR or plant biotech. In short: the revolution is gaining momentum and holds a great promise for health and food alike.
Total number of CRISPR patent applications worldwide per year from 1984 to 2018.
Fueled by digitalization, growing connectivity, and falling costs, important advances in biotechnology are intertwined with more systemic shift in how bio-innovation is undertaken and who is involved. Microbiome technologies, advanced genomics, gene editing and synthetic biology are among key enabling technologies that have the potential to change the face of bio-innovation. This broader redefinition of bio-innovation creates new prospects to help address important nutrition, environmental and development needs.
World Economic Forum, Bio-Innovation Dialogue Initiative
As a leading life science company, Bayer is aligned with the long-term market trends in health and nutrition and offers innovative and sustainable solutions to tackle some of the key challenges for humanity. Bayer brings to the table an extensive knowledge of human and plant science, supported by its expertise in regulatory processes and an impressive global footprint to ultimately bring innovations from labs to market. https://www.youtube-nocookie.com/embed/EYE1gya7XiM?autoplay=1&start=0&rel=0
The Bio Revolution marks the beginning of a new era: Innovations enabled by the convergence of biology and technology have the potential to significantly improve our lives, our nutrition, and our health.
Did you know that Bayer is at the forefront of the wave of innovation coming from the Bio Revolution?
The Bio Revolution is expected to transform healthcare and agriculture over the next decades – but the revolution is already happening now. With its newly established cell and gene therapy platform in Pharmaceuticals and innovative gene-editing tools such as CRISPR, Bayer operates at the core of the Bio Revolution and has tremendous opportunities to improve health and nutrition.
In Pharma, Bayer’s new Cell & Gene Therapy (CGT) platform steers our strategy in the area and orchestrates our activities along the value chain providing an innovation ecosystem for the companies – including BlueRock Therapeutics and Asklepios BioPharmaceutical (AskBio), which are fully owned by Bayer but operate autonomously. These therapies hold the potential to significantly impact patients’ lives by moving from treating symptoms to potentially curative approaches.
Bayer’s development portfolio of cell and gene therapies already comprises eight advanced assets in different stages of clinical development. These are applicable in multiple therapeutic areas with high unmet need, such as neurodegenerative, neuromuscular and cardiovascular indications, with programs in Pompe disease, Parkinson’s disease, hemophilia A, and congestive heart failure. With over 15 preclinical assets in the cell and gene therapy field, the pipeline is expected to grow steadily year by year.
Yet Bayer is not only using biotechnology to advance health – the promise for agriculture is just as inspiring. In the Crop Science Division, for example, tools like CRISPR can make changes to plant DNA with more precision than ever before and make plants more weather- or disease-resistant, enabling farmers to grow more or better-quality products under changing conditions.
Advancing genetic solutions for a sustainable future (1)PreviousNext
Did you know that Leaps by Bayer invests into potentially disruptive technologies to tackle some of the largest, unsolved challenges in the life sciences?
With Leaps by Bayer – our impact investment approach utilizing venture capital – we are constantly scanning for additional potential breakthroughs that hold promise to either cure or treat people from diseases or help feed a growing population with less impact on the environment.
$1 Billion
Since 2015, Leaps by Bayer has invested over $1 billion in ventures that tackle fundamental breakthroughs and shift core paradigms in our industries.
Leaps by Bayer has an investment focus on potentially disruptive solutions in the fields of healthcare and agriculture. The Leaps investment approach is remarkable: It aims to invest into or build up new innovative companies. Bayer supports those companies by enabling the exchange of proprietary assets, which can include sharing own patents or providing access to the Bayer network’s technical capabilities and 150 years of expertise. The companies remain autonomous with respect to decision making, while Leaps facilitates and supports them in a so-called active incubation process. Experienced team members actively engage in the young companies’ development by providing resources and helping them to steer the initial strategic direction. Today, the investment portfolio includes more than 35 companies advancing potential breakthrough technologies.
Leaps is our way of thinking big.
Werner Baumann, CEO of Bayer AG
Many Leaps ventures have made significant progress towards unlocking the potential of new technology platforms with a promising and transformative potential. BlueRock Therapeutics, for example, started as a Leaps investment and is now an integral part of Bayer’s CGT platform and just received clearance to proceed with a phase I trial in Parkinson’s disease.
Other companies, like the biopharmaceutical player Triumvira, are specialized on next generation immuno-oncology treatments. Triumvira focuses on novel T-cell therapies that aim to be safer and more efficacious than current cell therapy cancer treatments. Treating, curing and preventing cancer is one of the focus areas of Leaps by Bayer, since this group of diseases still represents one of today’s biggest health challenges with limited curative or preventative therapies available.
We face a huge disease burden, and the way we produce food isn’t sustainable for the planet. I believe the Bio Revolution can help us overcome these issues.
Jürgen Eckhardt, Head of Leaps by Bayer
Leaps is also investing in the development of sustainable biotechnological solutions in the field of agriculture. One of the ventures in this field is Joyn Bio, a company that aims to significantly reduce the environmental impact of synthetic nitrogen fertilizers through a technology that fixes nitrogen into the soil. Nitrogen is one of the most important nutrients essential for every plant to grow, however, its use and production as a fertilizer is estimated to contribute 3-5% to all global greenhouse gas emissions. Joyn Bio is working on an engineered microbe that enables cereal crops like corn, wheat, and rice to convert nitrogen from the air into a form they can use to grow. This technology may have the potential to help farmers use nitrogen in new ways, and as a result, reduce agriculture’s environmental footprint.
The Leaps by Bayer investment portfolio includes more than 35 companies.
At least that’s what Bayer says. All I know is that they’re still running the show.
To be continued? Our work and existence, as media and people, is funded solely by our most generous supporters. But we’re not really covering our costs so far, and we’re in dire needs to upgrade our equipment, especially for video production. Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!
! Articles can always be subject of later editing as a way of perfecting them
We gave up on our profit shares from masks, if you want to help us, please use the donation button! We think frequent mask use, even short term use can be bad for you, but if you have no way around them, at least send a message of consciousness. Get it here!